New Ebola vaccine faces key test

May 18, 2018

The experimental Ebola vaccine dubbed rVSV-ZEBOV has shown promising signs that it can contain the spread of the prolific killer virus.

With a new Ebola outbreak in the Democratic Republic of Congo triggering fears of a regional threat, the vaccine is about to face its toughest test.

The single-dose injection—developed by pharma company Merck and funded by the World Health Organization (WHO) and Canada's public health agency—has been approved for use by the Kinshasa government.

Roughly 7,500 doses have been sent to Equateur province in the northwest of the DRC. Here is what we know about the vaccine.

What is rVSV-ZEBOV?

It uses a modified version of the (VSV), which causes illness in rodents, cattle, pigs and horses, but is not dangerous to humans.

The vaccine prompts the human body to develop antibodies against the invader so that when Ebola attacks, the antibodies are quick to identify it and fight back.

Clinical trials involving 16,000 volunteers in Africa, Europe and the United States have indicated it may be 100 percent effective.

The vaccine does not contain any live Ebola virus.

It can trigger side effects like cold or flu-like symptoms and swelling at the point of injection.

Can it stop an epidemic?

The "vaccine is an additional tool," WHO spokesman Tarik Jasarevic told reporters in Geneva on Friday. "It does not replace all the other elements of the response."

Because rVSV-ZEBOV remains experimental and has not been tested in the height of the epidemic, it is premature to assume that it alone can contain Ebola's spread.

The epicentre of the outbreak is also an extremely remote, rural part of DR Congo, making access difficult. WHO has therefore conceded that "getting the vaccination teams to the affected area will be challenging".

The vaccine also has to be stored at temperatures as low as minus 80 degrees Celsius (-112 degrees Fahrenheit), so keeping it stable in an area with poor infrastructure creates additional complications.

Are there enough doses ready?

In addition to the doses that WHO has sent to DRC and a small reserve stock in Geneva, Merck has said it has 300,000 doses ready for the UN's use free of charge, according to Jasarevic.

WHO estimates that for every confirmed Ebola case, 100 to 150 of that patient's contacts should be vaccinated.

That number could go up for urban cases, given the increased frequency of close human contact in cities.

As of Friday, there were 31 suspected or probable cases in the current outbreak, plus 14 that have been laboratory confirmed.

Health workers and other responders—like those tasked with burying Ebola victims—should also be vaccinated, WHO said.

A WHO spokesman told reporters it was a "targeted vaccination" and therefore not for the "general population".

Gavi, the alliance, has given $1 million towards the operational costs in the DRC campaign, in addition to other support donated to WHO.

Jasarevic said the UN health agency was aiming to start vaccinations in Equateur as soon as possible.

Explore further: Congo's health ministry says doses of Ebola vaccine arrive

Related Stories

Congo's health ministry says doses of Ebola vaccine arrive

May 16, 2018
Thousands of doses of the experimental Ebola vaccine have arrived in Congo's capital amid the latest outbreak of the deadly disease, the health ministry said Wednesday.

Congo approves use of experimental Ebola vaccine, WHO says

May 14, 2018
Congo has agreed to allow the World Health Organization to use an experimental Ebola vaccine to combat an outbreak announced last week, the WHO director-general said Monday.

Ebola reaches an urban area in Congo. What now?

May 17, 2018
The global health community gulped Thursday with the announcement that a case of Ebola had been confirmed in a city of more than 1 million in Congo, bringing the latest outbreak of the often deadly hemorrhagic fever out of ...

Congo's Ebola outbreak reports first confirmed urban case

May 17, 2018
Congo's latest Ebola outbreak has spread to a city of more than 1 million people, a worrying shift as the deadly virus risks traveling more easily in densely populated areas.

WHO reports new Ebola case in DR Congo, vaccine this week

May 14, 2018
The head of the World Health Organization said Sunday there has been another reported case of Ebola in the Democratic Republic of Congo and that an experimental vaccine to fight the disease is expected to become available ...

'Major, major game-changer': Ebola spreads to big Congo city

May 17, 2018
Congo's Ebola outbreak has spread to a crossroads city of more than 1 million people in a troubling turn that marks the first time the vast, impoverished country has encountered the lethal virus in an urban area.

Recommended for you

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

Maternally acquired Zika immunity can increase dengue disease severity in mouse pups

November 14, 2018
To say that the immune system is complex is an understatement: an immune response protective in one context can turn deadly over time, as evidenced by numerous epidemiological studies on dengue infection, spanning multiple ...

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).

Discovery suggests new route to fight infection, disease

November 14, 2018
New research reveals how a single protein interferes with the immune system when exposed to the bacterium that causes Legionnaires' disease, findings that could have broad implications for development of medicines to fight ...

Synthetic DNA-delivered antibodies protect against Ebola in preclinical studies

November 13, 2018
Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results, published ...

Scientists illuminate causes of hepatitis B virus-associated acute liver failure

November 13, 2018
National Institutes of Health scientists and their collaborators found that hepatitis B virus (HBV)-associated acute liver failure (ALF)—a rare condition that can turn fatal within days without liver transplantation—results ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.